Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
about
Identification of novel human dipeptidyl peptidase-IV inhibitors of natural origin (part I): virtual screening and activity assaysGenetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.Changes in Adenosine Deaminase Activity in Patients with Type 2 Diabetes Mellitus and Effect of DPP-4 Inhibitor Treatment on ADA Activity.Comprehensive analysis of the Co-structures of dipeptidyl peptidase IV and its inhibitorRecent Advances in Effect-directed Enzyme Assays based on Thin-layer Chromatography.Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition.Dipeptidyl peptidase-IV and related molecules: markers of malignancy?Novel DPP-4 inhibitors against diabetes.Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.Finding a Potential Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for Type-2 Diabetes Treatment Based on Molecular Docking, Pharmacophore Generation, and Molecular Dynamics Simulation.Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.
P2860
Q28483681-5E743FC6-DDA7-4E16-BB15-5538AC80153DQ33428789-F9722E22-0164-440D-B258-E75AEB954A91Q35067242-8FB9587F-52B2-4ED0-8753-2F52185796B2Q36095299-C9C33BD7-0613-4C4C-8681-8BBD261578BFQ36266184-C947ABB7-BE0D-42D2-AE60-EED88DA54DD5Q37603371-8EF7CDDD-A689-4BFE-BD94-70F8172C5AB1Q38089765-25867C49-95AB-4E35-80A1-8292E95618D3Q38221278-9F3440C1-5C20-4808-8C87-6371DF10262AQ39646093-47B80185-DE2C-446F-A3FC-1F8E6370A58AQ41812639-1E6F45D0-D544-4252-AA5E-ACDBECF9A8BBQ45327491-681D9E45-A94E-41A0-BC93-9F444747856C
P2860
Rational design of a novel, potent, and orally bioavailable cyclohexylamine DPP-4 inhibitor by application of molecular modeling and X-ray crystallography of sitagliptin
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Rational design of a novel, po ...... crystallography of sitagliptin
@ast
Rational design of a novel, po ...... crystallography of sitagliptin
@en
Rational design of a novel, po ...... crystallography of sitagliptin
@nl
type
label
Rational design of a novel, po ...... crystallography of sitagliptin
@ast
Rational design of a novel, po ...... crystallography of sitagliptin
@en
Rational design of a novel, po ...... crystallography of sitagliptin
@nl
prefLabel
Rational design of a novel, po ...... crystallography of sitagliptin
@ast
Rational design of a novel, po ...... crystallography of sitagliptin
@en
Rational design of a novel, po ...... crystallography of sitagliptin
@nl
P2093
P921
P3181
P1476
Rational design of a novel, po ...... crystallography of sitagliptin
@en
P2093
Aleksandr Petrov
Ann E Weber
Dennis Feng
George A Doss
George Eiermann
Huaibing He
Joe W Becker
Kathy Lyons
P304
P3181
P356
10.1016/J.BMCL.2007.03.095
P407
P577
2007-06-15T00:00:00Z